Deal facts
- Buyer
- Biogen Inc.
- Target
- Apellis Pharmaceuticals, Inc.
- Deal value
- Not disclosed
- Announced
- 31 March 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash, earn-out
Sources
Biogen Inc. has agreed to acquire Apellis Pharmaceuticals, Inc. in a going private transaction valued at an undisclosed sum. The deal, announced on 31 March 2026, involves a consideration structure comprising cash and an earn-out component. Both the buyer and the target are based in the United States within the healthcare sector. The transaction was completed on 14 May 2026, marking the end of Apellis as a publicly listed entity.
The acquisition allows Biogen to integrate Apellis into its broader portfolio of therapeutic assets. No specific financial figures were reported for the final transaction value. Regulatory approvals were obtained to facilitate the completion of the deal within the specified timeframe. The transaction is now fully concluded with no further conditions pending.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
Biogen Inc. completes acquisition of Apellis Pharmaceuticals, Inc.
Introductory Note As previously disclosed, on March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Biogen”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Biogen (“Purchaser”). Pursuant to the Merger Agreement, o
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
CCP PAW 2 LIMITED to acquire ANIMALCARE GROUP PLC
CCP PAW 2 Limited has agreed to acquire Animalcare Group Plc in a going private transaction. The deal was announced and completed on 30 July 2026. Both the buyer and the…
- Buyer
- CCP PAW 2 LIMITED
- Target
- ANIMALCARE GROUP PLC
- Deal value
- Not disclosed
- Deal type
- going private
argenx BV to acquire Forte Biosciences, Inc.
argenx BV has agreed to acquire Forte Biosciences, Inc. in a going private transaction valued at USD 2.2 billion. The Belgian listed biotechnology company is purchasing…
- Buyer
- argenx BV
- Target
- Forte Biosciences, Inc.
- Deal value
- USD 2,200,000,000
- Deal type
- going private
Vertex Pharmaceuticals Incorporated to acquire Crinetics Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated has agreed to acquire Crinetics Pharmaceuticals, Inc. in a going private transaction valued at $10 billion. The deal, announced on 6…
- Buyer
- Vertex Pharmaceuticals Incorporated
- Target
- Crinetics Pharmaceuticals, Inc.
- Deal value
- USD 10,000,000,000
- Deal type
- going private
Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.
Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…
- Buyer
- Trafalgar Asset Management, LLC
- Target
- The Greater Cannabis Company, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.
Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…
- Buyer
- Hanmi Pharmaceuticals Co. Ltd.
- Target
- Aptose Biosciences Inc.
- Deal value
- USD 3,466,470
- Deal type
- going private
Buyer history
Biogen Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive